Abbott’s studies show CGM technology linked to lower heart hospitalisation risk
Abbott's REFLECT real-world retrospective studies indicate that FreeStyle Libre continuous glucose monitoring (CGM) technology use is linked to a significant…
Cardiovascular
-
-
First subject enrolled in BioCardia’s Phase III heart failure therapy trial
BioCardia has announced the enrolment of the first subject in the randomised, double-blind, placebo-controlled Phase III CardiAMP heart failure (HF)…
-
Renibus completes enrolment in RBT-1 trial to reduce post-cardiac surgery risk
Renibus Therapeutics has completed subject enrolment for the randomised Phase III PROTECT trial, assessing RBT-1 (stannic protoporfin/iron sucrose) in minimising…
-
People with narcolepsy at increased risk for CVD
Narcolepsy is a sleep disorder that specifically affects the rapid eye movement (REM) cycle. Hallmark symptoms of narcolepsy include excessive…
-
Northwestern University enrols first subject in trial of drug for pericarditis
Northwestern University in Illinois, US, has enrolled the first subject in a Phase III trial of Cardiol Therapeutics' drug candidate,…
-
DSMB recommends continuation of BioCardia’s cell therapy trial for heart failure
An independent Data Safety Monitoring Board (DSMB) has recommended the continuation of BioCardia's Phase I/II CardiALLO-HF trial as designed. The…
-
Emory begins enrolment for BioCardia’s trial of ischemic heart failure therapy
Emory University School of Medicine, US, has commenced subject enrolment for BioCardia’s Phase III CardiAMP HF II trial of CardiAMP…
-
ACC 25: Biocardia’s CardiAMP trial fails but cell therapy potential remains
At the American College of Cardiology’s 74th Annual Scientific Session in Chicago, results were reported in a late-breaker trials session…
-
ACC 25: semaglutide reduces total cardiovascular events in latest SELECT results
At the American College of Cardiology’s 74th Annual Scientific Session in Chicago, results were released from a study by Lincoff…
-
Mineralys’s stock soars as hypertension pill scores in two pivotal trials
Mineralys Therapeutics’s oral hypertension therapy, lorundrostat, has met the primary endpoint in two pivotal studies, boosting the company’s stock price.…
